Processa Pharmaceuticals Ebitda Over Time
| PCSA Stock | USD 1.16 0.18 18.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Processa Pharmaceuticals Performance and Processa Pharmaceuticals Correlation. Processa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Processa Pharmaceuticals and related stocks such as Alpha Cognition, Eupraxia Pharmaceuticals, and Acurx Pharmaceuticals LLC Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.8 M) | (12.1 M) | (14.6 M) | (15.3 M) |
| FENC | (1.6 M) | (3.4 M) | (3.6 M) | (1.9 M) | (3.6 M) | (3.1 M) | (3 M) | (6.8 M) | (10.6 M) | (12.9 M) | (17.9 M) | (123 K) | (22.6 M) | (12.4 M) | (11.7 M) |
| SABS | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | 21.1 M | (11.7 M) | (15.1 M) | (38.1 M) | (36.2 M) |
| THRD | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (29.6 M) | (40.3 M) | (30.8 M) | (32.3 M) |
| INBX | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (28.8 M) | (42.6 M) | (66.4 M) | (75.4 M) | (127.9 M) | (206.7 M) | (196.4 M) |
| CELC | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (3.3 M) | (5.8 M) | (7.5 M) | (7.4 M) | (9.2 M) | (28.1 M) | (39.2 M) | (58.3 M) | (55.4 M) |
| ELVN | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (11.3 M) | (24.1 M) | (9.3 M) | (24.6 M) | (38.6 M) | (81.9 M) | (77.8 M) |
| ANTX | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (7.3 M) | (21.5 M) | (43.5 M) | 4.9 M | 5.1 M |
| IKT | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (2.8 M) | (14.8 M) | (18.1 M) | (19.9 M) | (18.9 M) |
| PMVP | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (26.2 M) | (34.6 M) | (58 M) | (76.7 M) | (78.9 M) | (74.9 M) |
| ANEB | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (30.2 M) | 5.6 K | (11.8 M) | (8.1 M) | (8.5 M) |
| AKTX | (792 K) | (2.4 M) | (1.8 M) | (3.7 M) | (10.2 M) | (34.3 M) | (27.1 M) | (37.2 M) | (37.2 M) | (25 M) | (20.4 M) | (17.2 M) | (23.1 M) | (16.8 M) | (17.6 M) |
| ARMP | (5 M) | (3.8 M) | (4 M) | 25.7 M | (51.2 M) | (19.5 M) | (8.5 M) | (6.2 M) | (8.4 M) | (18.2 M) | (20.4 M) | (22.7 M) | (36.1 M) | (39.9 M) | (37.9 M) |
Processa Pharmaceuticals and related stocks such as Alpha Cognition, Eupraxia Pharmaceuticals, and Acurx Pharmaceuticals LLC Ebitda description
My Equities
My Current Equities and Potential Positions
| Processa Pharmaceuticals | PCSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Maryland; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.16
Check out Processa Pharmaceuticals Performance and Processa Pharmaceuticals Correlation. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Processa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.